Allergan Inactive 10-Q2004 Q1 Quarterly report

Filed: 30 Apr 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: Aa, abroad, accident, accidental, Adjudication, affiliated, approach, asBotox®andTazorac, assumption, authorized, bank, Beaufour, biologic, block, Bond, borne, Brandt, broaden, candidate, cGMP, choice, chosen, civil, clarification, cleanup, compliant, comply, conference, contamination, coordinate, coordinating, coverage, criminal, demonstrate, developmental, direct, directed, discover, dispute, disseminate, diversification, duly, enacted, environmental, Eric, erosion, evergreen, exerted, exhibit, expand, expanding, experienced, expertise, Falcon, forAlphagan, forTazorac, found, fromZymar, genericAlphagan, grown, holding, identification, illegal, index, Internet, labor, leave, left, lengthy, long, mandated, mechanism, Medicare, Mexican, Mexico, Modernization, Moody, noncompliance, nonqualified, ourBotox, payer, permissible, peso, physician, platform, population, postretirement, preclinical, pressure, ratio, rebalancing, refusal, repaid, repatriation, Restated, retiree, revocation, run, safe, safely, satisfaction, secondary, short, slightly, submit, subsidy, suggested, suspension, sustained, targeted, tariff, theAcular®patent, thereunto, toxic, unamortizable, unchanged, undersigned, unexpected, vacated, warning, weak, widespread, Yield

Removed: adjusting, adult, advisory, affirmed, age, AGN, andLumigan, androgen, andZymar, approvedBotox, artificial, asBotox, AVO, Banc, Bausch, began, body, book, Brazil, British, called, case, cataract, Central, channel, Chief, closure, Code, comprised, contact, coveringAlphagan, DEA, decided, decision, decreasing, device, discontinued, disposal, duration, effected, EITF, elapsed, element, Emerging, En, equal, exchanged, exercised, exit, expedited, expended, extend, failing, Farallon, finalized, firmly, footnote, formed, fully, funded, granting, grew, guarantee, guarantor, hedging, hypotensive, incidental, indefinitely, Indirect, informational, intraocular, issuance, issuing, kinase, lesser, letter, located, Lomb, longer, low, mature, memantine, men, modified, Multiple, neovascularization, newly, noncompetitive, nonemployee, October, offering, optical, Orange, overturn, ownership, page, partial, perfunctory, Petition, Pharma, photodynamic, planned, pound, preferBotox, presently, productAvage, project, prominent, prospectively, publicly, realize, recast, recruiting, redeemed, reflected, refractive, Rehearing, relate, relationship, relocation, representing, respond, restructure, restructuring, retail, retinal, salary, scope, separation, sharing, solution, sought, structure, surgery, surgical, symbol, taxable, tazarotene, theAcular, theAlphagan, transferred, transitional, tyrosine, unamortized, undertaken, unrelated, VITRAX, women, workforce, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Allergan similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

The following certifications are being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350 and in accordance with SEC Release No. 33-8238. These certifications shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Allergan, Inc., a Delaware corporation (the “Company”), hereby certifies, to his knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the period ended March 26, 2004 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: April30, 2004	/s/ David E.I. Pyott
	David E.I. Pyott, Chairman of the Board, President and Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Allergan, Inc. and will be retained by Allergan, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Certification of Principal Financial Officer

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: April30, 2004	/s/ Eric K. Brandt
	Eric K. Brandt, Executive Vice President, Finance, Strategy and Corporate Development (Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.